Alidac Pharmaceuticals, the wholly-owned subsidiary of Zydus Cadila has received zero observations, from the US health regulator.

The US health regulator had conducted an inspection of its manufacturing facility located at SEZ, Ahmedabad. This site manufactures oncology injectables for the regulated markets

Further, in a filing to BSE Zydus Cadila stated, “The US Food and Drug Administration (USFDA) inspected the manufacturing facility of our wholly-owned subsidiary, Alidac Pharmaceuticals Ltd located at SEZ, Ahmedabad from May 28 to June 5, 2018. At the end of the inspection, no observation (483) is issued.”

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week